Alluvi, previously BI 4744, offers a promising advance in weight management care. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates compelling effectiveness in clinical trials, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/